Platelet factor 4 (Repligen)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePlatelet factor 4 (Repligen)
Drug Alias NamerPF4RG 1001IroplactPF4Endostatin B +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionAngiogenesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsBlood Coagulation DisordersColorectal NeoplasmsCarcinoma, Renal Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRepligen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRepligen
Active IndicationsN/A
Inactive IndicationsBlood Coagulation DisordersColorectal NeoplasmsCarcinoma, Renal Cell +[6] 

Other Information

ATC CodeN/A
Related LinksN/A